This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Sanofi branded clouded background image

Latest Education

Sohail Akhtar - 29.03.24

Education17 Apr 2024

Diabetes UK 2024: Navigating Hyperglycaemia after GLP-1s with Insulin

Slides and recording of Diabetes UK 2024 - in collaboration with Diabetes Specialist Nurse Forum UK

Sohail Akhtar - 29.03.24

Education17 Apr 2024

Diabetes UK 2024: Connecting the Dots: Benefits of pen connectivity for people living with diabetes

Slides and recording of Diabetes UK 2024 - in collaboration with Diabetes Specialist Nurse Forum UK

Sohail Akhtar - 29.03.24

Education17 Apr 2024

Diabetes UK 2024: Sustainably scripting tomorrow with Sanofi's Planet Cares Programme and Pen Recycling pilot

Slides and recording of Diabetes UK 2024 - in collaboration with Diabetes Specialist Nurse Forum UK

Education23 Oct 2023

The Continuing Role of Secondary Care in Lipid Optimisation Post-ACS

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Education23 Oct 2023

What Insulins Do I Need In My Toolbox To Support People With Type 2 Diabetes

Lantus® (insulin glargine 100 units/mL) Prescribing Information UK Toujeo® (insulin glargine 300 units/mL) Prescribing Information UK

Education23 Oct 2023

Implementing Artificial Intelligence to Risk Stratify, Manage and Refer Patients

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Education23 Oct 2023

New Approaches and Innovation in Lipid Services – Strengthening the Relationship between Primary and Secondary Care

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Education23 Oct 2023

What the InRange Study Can Teach Us About Time-In-Range (TIR)

Toujeo® (insulin glargine 300 units/mL) Prescribing Information

Education23 Oct 2023

Strengthening the Interface Between Primary and Secondary Care

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

MAT-XU-2305049 (v2.0) Date of preparation: February 2024

Therapeutic Areas
- Cardiology
  - Dyslipidaemia
  - Thrombosis
- Dermatology
  - Atopic Dermatitis
- Diabetes
  - Type 1 Diabetes
  - Type 2 Diabetes
- Neurology
  - Multiple Sclerosis
- Oncology
  - Multiple Myeloma
  - Other Oncology Topics
- Rare Disease
- Respiratory
  - COPD
- Transplant
  - Transplant
- Vaccines
- Other Topics
  - General Topics
  - Payor
Articles
- Cardiology
  - Dyslipidaemia
  - Thrombosis
- Dermatology
  - Atopic Dermatitis
- Diabetes
  - Type 1 Diabetes
  - Type 2 Diabetes
- Neurology
  - Multiple Sclerosis
- Oncology
  - Multiple Myeloma
  - Other Oncology Topics
- Rare Disease
- Respiratory
  - COPD
- Transplant
  - Transplant
- Vaccines
  - Influenza
- Other Topics
  - General Topics
Resources
- Cardiology
  - Dyslipidaemia
- Dermatology
  - Atopic Dermatitis
- Diabetes
  - Type 1 Diabetes
- Oncology
  - Multiple Myeloma
- Rare Disease
- Vaccines
- Other Topics
  - Payor
Tools
- Dermatology
  - Atopic Dermatitis
Events
- Diabetes
  - Type 2 Diabetes
Education
- Cardiology
  - Dyslipidaemia
- Diabetes
  - Type 1 Diabetes
  - Type 2 Diabetes
- Transplant
  - Transplant
- Vaccines
  - Other Vaccines Topics
Products